ConductScience.org, home

Paper39367387

AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.

Vandewalle N and 8 others. Exp Hematol Oncol, 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies. Papers, record 39367387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39367387

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.
PubMed
Journal
Exp Hematol Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.41, provisional
iCite
Revised in PubMed
2024-10-07
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vandewalle NNiels
2De Beule NNathan
3De Becker AAnn
4De Bruyne EElke
5Menu EEline
6Vanderkerken KKarin
7Breckpot KKarine
8Devoogdt NNick
9De Veirman KKim

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
G0A8522N, 1S66121NFonds voor Wetenschappelijk Onderzoek VlaanderenPubMed
G0A8522N, 1S66121NFonds voor Wetenschappelijk Onderzoek VlaanderenPubMed
SRP-84Vrije Universiteit BrusselPubMed
KotK_VUB/ 2021/12786/1Kom Op Tegen KankerPubMed

Source PubMed

Download CSV of grants

References152

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126794130Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis.Dis Model Mech2016https://conductscience.org/library/papers/26794130PubMed
224904064Axl receptor tyrosine kinase expression in breast cancer.J Clin Pathol2014https://conductscience.org/library/papers/24904064PubMed
317325667A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.Oncogene2007https://conductscience.org/library/papers/17325667PubMed
49671397Determinants for transformation induced by the Axl receptor tyrosine kinase.Oncogene1998https://conductscience.org/library/papers/9671397PubMed
530189359AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking.Neoplasia2018https://conductscience.org/library/papers/30189359PubMed
634244439The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34244439PubMed
732660000Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.Cancers (Basel)2020https://conductscience.org/library/papers/32660000PubMed
833268594TP-0903 is active in models of drug-resistant acute myeloid leukemia.JCI Insight2020https://conductscience.org/library/papers/33268594PubMed
928645776Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Lancet Oncol2017https://conductscience.org/library/papers/28645776PubMed
1034266948Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34266948PubMed
1123648337AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival.Mol Cell Endocrinol2013https://conductscience.org/library/papers/23648337PubMed
1229386018Targeting Gas6/TAM in cancer cells and tumor microenvironment.Mol Cancer2018https://conductscience.org/library/papers/29386018PubMed
1333127875New directions for emerging therapies in acute myeloid leukemia: the next chapter.Blood Cancer J2020https://conductscience.org/library/papers/33127875PubMed
1424022140First Axl inhibitor enters clinical trials.Nat Biotechnol2013https://conductscience.org/library/papers/24022140PubMed
1535311091The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.Front Oncol2022https://conductscience.org/library/papers/35311091PubMed
1626763248Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.Clin Cancer Res2016https://conductscience.org/library/papers/26763248PubMed
1727549806Axl signaling induces development of natural killer cells in vitro and in vivo.Protoplasma2017https://conductscience.org/library/papers/27549806PubMed
1817655729FLT3 inhibition in acute myeloid leukaemia.Br J Haematol2007https://conductscience.org/library/papers/17655729PubMed
1925344858Axl as a mediator of cellular growth and survival.Oncotarget2014https://conductscience.org/library/papers/25344858PubMed
2034400415Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia.Clin Cancer Res2021https://conductscience.org/library/papers/34400415PubMed

See all 152 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42466468FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches.RSC Adv2026https://conductscience.org/library/papers/42466468PubMed
42101422TAM receptor tyrosine kinases as potential mediators of the non-lytic spread of non-enveloped viruses.Biochem Soc Trans2026https://conductscience.org/library/papers/42101422PubMed
41916916[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance].Zhongguo Fei Ai Za Zhi2026https://conductscience.org/library/papers/41916916PubMed
41446729IFNγ signaling drives resistance to FLT3 inhibition in acute myeloid leukemia.iScience2025https://conductscience.org/library/papers/41446729PubMed
41095933Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib.J Clin Med2025https://conductscience.org/library/papers/41095933PubMed
41011010The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact.Medicina (Kaunas)2025https://conductscience.org/library/papers/41011010PubMed
40464185Recent Advances in FLT3-Based Dual Inhibitors: A Promising Strategy for the Treatment of Acute Myeloid Leukemia.Curr Med Chem2026https://conductscience.org/library/papers/40464185PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
AXL558PubTator's text mininghttps://conductscience.org/library/genes/558

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39367387

GET https://conductscience.org/api/papers/v1/39367387/references?page=2